Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2022; 28(21): 2291-2301
Published online Jun 7, 2022. doi: 10.3748/wjg.v28.i21.2291
Published online Jun 7, 2022. doi: 10.3748/wjg.v28.i21.2291
Serological biomarkers for management of primary sclerosing cholangitis
David Tornai, Maria Papp, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen H-4032, Hajdu-Bihar, Hungary
David Tornai, Maria Papp, European Reference Network on Hepatological Diseases, ERN RARE-LIVER, Debrecen H-4032, Hajdu-Bihar, Hungary
Peter Laszlo Ven, The First Department of Medicine, Division of Gastroenterology, University of Pécs, Pécs H-7624, Baranya, Hungary
Peter Laszlo Ven, Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen H-4032, Hajdu-Bihar, Hungary
Peter Laszlo Lakatos, Division of Gastroenterology, McGill University Health Centre, Montreal QC H4A 3J1, Quebec, Canada
Peter Laszlo Lakatos, The First Department of Medicine, Semmelweis University, Budapest H-1083, Pest, Hungary
Author contributions: Tornai D and Ven PL performed the literature review; Tornai D wrote the manuscript; Papp M and Lakatos PL supervised the work and provided expert insights; all authors have read and approved the final manuscript.
Supported by the Ministry of Innovation and Technology of Hungary from the National Research , Development and Innovation Fund, No. 138041; and the EFOP projects co-financed by the European Union and the European Social Fund , No. EFOP-3.6.1-16-2016-00022 .
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maria Papp, DSc, FEBG, MD, PhD, Full Professor, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, Debrecen H-4032, Hajdu-Bihar, Hungary. papp.maria@med.unideb.hu
Received: December 13, 2021
Peer-review started: December 13, 2021
First decision: January 23, 2022
Revised: February 1, 2022
Accepted: April 25, 2022
Article in press: April 25, 2022
Published online: June 7, 2022
Peer-review started: December 13, 2021
First decision: January 23, 2022
Revised: February 1, 2022
Accepted: April 25, 2022
Article in press: April 25, 2022
Published online: June 7, 2022
Core Tip
Core Tip: Recent advances in biomarker research may help clinicians identify relevant subgroups of primary sclerosing cholangitis (PSC) and assist everyday clinical work-up. However, a diagnostic biomarker is still an unmet need. On the other hand, several biomarkers have been reported to predict outcome in PSC; however, most of them have not been validated by subsequent studies. The IgA type anti-glycoprotein 2 antibody is the first one to be supported by a satisfactory number of clinical studies and could be incorporated into clinical practice. These discoveries also reveal different aspects of PSC providing with potential therapeutic targets.